Engineered nucleic acid-targeting nucleic acids

Inventors

Donohoue, Paul Daniel • May, Andrew Paul

Assignees

Caribou Biosciences Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11505808-B2

Patent

Publication Date

2022-11-22

Expiration Date


Abstract

The present disclosure provides engineered polynucleotide sequences that form scaffolds and nucleoprotein complexes comprising such engineered polynucleotide sequences that form scaffolds and nucleic acid binding proteins. Nucleic acid sequences encoding the engineered polynucleotide sequences that form scaffolds, as well as expression cassettes, vectors and cells comprising such polynucleotide sequences, are described. A variety of methods for making and using the engineered polynucleotide sequences that form scaffolds are also disclosed.

Core Innovation

The invention describes an engineered Class 2 Type II CRISPR-nucleic acid scaffold (NASC) for forming a Class 2 Type II CRISPR-NASC composition and a nucleoprotein complex with Class 2 Type II CRISPR-Cas9 proteins. The scaffold is built from engineered nucleic acid components that each include a spacer element with a nucleic acid target binding sequence, a repeat element with a repeat nucleic acid sequence, and a nucleic acid binding protein binding element with a double-stranded nucleic acid binding protein binding sequence. The spacer element is covalently connected with the repeat element, and the repeat element is covalently connected with the nucleic acid binding protein binding element.

The engineered nucleic acid components are configured so that each engineered nucleic acid component does not contain a stem formed by hydrogen-bonded base pairs capable of binding a Class 2 Type II CRISPR-Cas9 protein. Instead, the connection between the repeat nucleic acid sequence 1 and the repeat nucleic acid sequence 1C is formed through hydrogen-bonded base pairs. This hydrogen-bonded repeat connection forms the Class 2 Type II CRISPR-NASC composition, which then forms a nucleoprotein complex with a first and a second Class 2 Type II CRISPR-Cas9 protein prior to being introduced into the cell.

The disclosed scaffold architectures include engineered NASC-PC-CE and engineered NASC-PC-SCE concatenated-element constructions, including concatenated elements such as linkers, hairpins, nexus regions, repeats, and bulges, with optional effector/protein-binding sites. Variants include circular and multi-concatenate versions, and a split-nexus scaffold where a nexus element is split and re-associated through hydrogen bonding.

Claims Coverage

The independent claims recite ex vivo cell compositions containing an engineered Class 2 Type II CRISPR-NASC scaffold with two engineered nucleic acid components, including hydrogen-bonded repeat connections that enable a nucleoprotein complex with two Class 2 Type II CRISPR-Cas9 proteins prior to introduction into the cell. The inventive features emphasize covalently connected scaffold elements, a lack of a Cas9-binding stem in each component, and a hydrogen-bonded repeat connection that enables complex formation prior to introduction into the cell.

Engineered Class 2 Type II CRISPR-NASC scaffold in an ex vivo cell

A cell comprising a Class 2 Type II CRISPR-NASC composition formed by a first engineered nucleic acid component and a second engineered nucleic acid component, where each component includes spacer elements with target binding sequences, repeat elements, and nucleic acid binding protein binding elements with double-stranded nucleic acid binding protein binding sequences, and where each component does not contain a stem formed by hydrogen-bonded base pairs capable of binding a Class 2 Type II CRISPR-Cas9 protein.

Hydrogen-bonded repeat connection forms the scaffold association and nucleoprotein complex

A connection between the repeat nucleic acid sequence 1 and the repeat nucleic acid sequence 1C through hydrogen-bonded base pairs, wherein the connection forms the Class 2 Type II CRISPR-NASC composition and the Class 2 Type II CRISPR-NASC composition forms a nucleoprotein complex with a first Class 2 Type II CRISPR-Cas9 protein and a second Class 2 Type II CRISPR-Cas9 protein prior to being introduced into the cell.

Across the independent claims, the main inventive coverage is an ex vivo cell containing an engineered Class 2 Type II CRISPR-NASC scaffold built from covalently connected spacer-repeat-protein-binding elements, configured to lack Class 2 Type II CRISPR-Cas9 binding hydrogen-bonded stems within each component, with scaffold formation driven by hydrogen-bonded base-pair connections between repeat sequences to form a nucleoprotein complex with two Class 2 Type II CRISPR-Cas9 proteins prior to cell introduction.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Not explicitly described in patent.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.